CompoAtlas

Gélules CBD "Complexe antistress" 750 mg

Food supplement declared in France

Gélules CBD "Complexe antistress" 750 mg (Novaloa) is a food supplement declared in France. Status: withdrawn from the market on 30 October 2025. Main ingredients: Sedum roseum 262.5 mg per day, Ophiocordyceps sinensis 262.5 mg per day, Ganoderma lucidum(Curtis 262.5 mg per day, Cannabis sativa 50 mg per day. 1 point in its composition requires a check (prohibited substance, dose or novel food).

Brand
Novaloa
Food business operator placing the product on the market
Nova CM Distribution
Status
Withdrawn from the market on 30 October 2025
Form
Capsule
Daily dose
2 gélules, soit 1,2 g de poudre
Directions for use
Gélules à avaler.
Intended populations
General population, Men, Women
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Concurrent alcohol consumption, Liver problems, Taking antidepressants, Taking medication, Children (under 6), Children (under 10)
Objectives stated by the manufacturer (these are not authorised claims)
Autre : Anti-stress

Declaration 260150, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Sedum roseum (L.) Scop.RhizomeExtrait sec alcoolique262.5 mg
Ophiocordyceps sinensisCarpophoreExtrait sec aqueux262.5 mg
Ganoderma lucidum(Curtis ex Fr.) P.Karst.CarpophoreExtrait sec aqueux262.5 mg
Cannabis sativa L.Sommités fleuriesExtrait au CO2 supercritique50 mg

Additives

E464

Other ingredients

huile de noix de coco fractionnée

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Consommation interdite aux mineurs et aux femmes enceintes et / ou allaitantes. En cas de problème hépatique, consommation fortement déconseillée. Prises d’alcool et / ou de médicaments concomitantes fortement déconseillées. Consulter un médecin en cas de doute.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Sedum roseum (L.) Scop.
    Read the warning, when it applies and the studies cited

    RHODIOLA - RHODIOLA ROSEA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).

    Sources cited by Health Canada (1)
    • EMA 2024: 20 March 2024 EMA/HMPC/24177/2023 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Rhodiola rosea L., rhizoma et radix Final - Revision 1. Amsterdam (NL): European Medicines Agency, Science Medicines Health. [Accessed 2025 January 21]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-rhodiola-rosea-l-rhizoma-et-radix-revision-1_en.pdf

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking antidepressant medication, hormone replacement therapy (HRT) or birth control medication (HC 2018; Iovieno et al. 2011; Olsson et al. 2009; Brown et al. 2002).

    Sources cited by Health Canada (4)
    • Brown RP, Gerbarg PL, Ramazanov Z. Rhodiola rosea: A Phytomedicinal Overview. HerbalGram 2002;56:40-52.
    • HC 2018: Health Canada. Canada Vigilance Adverse Reaction Online Database. Ottawa (ON): Marketed Health Products Directorate, Health Canada. [Accessed 2025 January 21]. Available from: https://cvp-pcv.hc-sc.gc.ca/arq-rei/index-eng.jsp
    • Iovieno, N., Dalton, ED., Fava, M., Mischoulon, D. Second-tier natural antidepressants: review and critique. Journal of Affective Disorders 2011;130(3): 343-357.
    • SC 2018: Santé Canada. Base de données en ligne des effets indésirables de Canada Vigilance. Ottawa (ON): Direction des produits de santé commercialisés, Santé Canada. [Consulté le 21 janvier 2025]. Disponible à : https://cvp-pcv.hc-sc.gc.ca/arq-rei/switchlocale.do?lang=fr&url=t.search.recherche

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you have bipolar disorder or bipolar spectrum disorder (Iovieno et al. 2011; Winston and Maimes 2007; Brown et al. 2002).

    Sources cited by Health Canada (3)
    • Brown RP, Gerbarg PL, Ramazanov Z. Rhodiola rosea: A Phytomedicinal Overview. HerbalGram 2002;56:40-52.
    • Iovieno, N., Dalton, ED., Fava, M., Mischoulon, D. Second-tier natural antidepressants: review and critique. Journal of Affective Disorders 2011;130(3): 343-357.
    • Winston D, Maimes S. Adaptogens: Herbs for Strength, Stamina, and Stress Relief. Rochester (VT): Healing Arts Press, 2007.

    Known adverse reactions

    Stop use if you experience irritability or insomnia (Pizzorno and Murray 2006; Kelly 2001).

    Sources cited by Health Canada (2)
    • Kelly GS. Rhodiola rosea: A Possible Plant Adaptogen. Alternative Medicine Review 2001;6(3): 293-302. PubMed Review article
    • Pizzorno JE, Murray MT, editors. Textbook of Natural Medicine. 3rd edition, volume 1. St. Louis (MI): Churchill Livingstone Elsevier; 2006.

    Health Canada monograph dated 31 October 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Brand : Novaloa

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Gélules CBD "Complexe antistress" 750 mg (Novaloa): composition and regulation”, https://compoatlas.com/en/supplements/products/260150-gelules-cbd-complexe-antistress-750-mg, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line